Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 2:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 86 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Severe Acne Vulgaris Clear all
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris

NCT03271021
View directory record Official record
Conditions
Acne Vulgaris
Interventions
FMX101, Vehicle Foam
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
9 Years and older
Enrollment
1,488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
98
States / cities
Phoenix, Arizona • Tucson, Arizona • Bryant, Arkansas + 83 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 2, 2026, 2:05 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Use of Oracea and Epiduo Forte in Severe Acne Patients

NCT03457636
View directory record Official record
Conditions
Acne
Interventions
Doxycycline Anhydrous 40 MG, Adapalene/Benzoyl Peroxide Gel 0.3-2.5%
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
12 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 2, 2026, 2:05 AM EDT
Completed Phase 3 Interventional Results available

Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa

NCT04179175
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
secukinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
29
States / cities
Rogers, Arkansas • San Diego, California • Whittier, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 2, 2026, 2:05 AM EDT
Completed Phase 4 Interventional Results available

Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Facial Acne

NCT00841776
View directory record Official record
Conditions
Acne
Interventions
Duac, Ziana gel
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Louisville, Kentucky • Mason, Ohio
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 2, 2026, 2:05 AM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Evaluation of Topical Treatments for Moderate-Severe Facial Acne Vulgaris

NCT02604680
View directory record Official record
Conditions
Acne Vulgaris
Interventions
BLI1100-1, BLI1100-2, BLI1100-3, BLI1100-4, Placebo
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
12 Years to 45 Years
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
50
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2017 · Synced Oct 2, 2026, 2:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of the Cutera Enlighten™ Laser With Micro-Lens Array (MLA) Handpiece Attachment

NCT03430921
View directory record Official record
Conditions
Scarring, Acne
Interventions
Enlighten™ Laser and a MLA Attachment
Device
Lead sponsor
Cutera Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 2, 2026, 2:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

enLighten Laser With MLA Handpiece for Treatment of Moderate and Severe Acne Scars

NCT03284333
View directory record Official record
Conditions
Acne Scars - Mixed Atrophic and Hypertrophic
Interventions
other
Device
Lead sponsor
Cutera Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Brisbane, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 2, 2026, 2:05 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris

NCT01498874
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Placebo, gevokizumab
Drug
Lead sponsor
XOMA (US) LLC
Industry
Eligibility
17 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
19
States / cities
Hot Springs, Arkansas • Riverside, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Oct 2, 2026, 2:05 AM EDT
Completed Not applicable Interventional

A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris

NCT01501799
View directory record Official record
Conditions
Acne Vulgaris
Interventions
adapalene 0.1% and benzoyl peroxide 2.5% topical gel, EPIDUO, Placebo (Vehicle Gel)
Drug
Lead sponsor
Actavis Mid-Atlantic LLC
Industry
Eligibility
12 Years to 40 Years
Enrollment
885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
8
States / cities
Fremont, California • Miami, Florida • Miramar, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2011 · Synced Oct 2, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne

NCT02998671
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CJM112, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Culver City, California • Sacramento, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 2, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)

NCT03852472
View directory record Official record
Conditions
Hidradenitis Suppurativa, Acne Inversa
Interventions
Avacopan, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
91
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 2, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne

NCT03497897
View directory record Official record
Conditions
Inflammatory Acne
Interventions
LYS006 20 mg, LYS006 2 mg, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
7
States / cities
Fremont, California • Santa Monica, California • Hialeah, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Oct 2, 2026, 2:05 AM EDT
Completed Phase 3 Interventional Results available

Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris

NCT00688064
View directory record Official record
Conditions
Severe Acne Vulgaris
Interventions
Adapalene BPO Gel associated with Doxycyline Hyclate, Vehicle Gel associated with Doxycycline Hyclate
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 35 Years
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
28
States / cities
Oceanside, California • San Diego, California • Denver, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 2, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults

NCT05080764
View directory record Official record
Conditions
Acne Vulgaris
Interventions
1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient), 3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 3h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Combination Product
Lead sponsor
Biofrontera Inc.
Industry
Eligibility
16 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
9
States / cities
Fountain Valley, California • San Diego, California • Delray Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 2, 2026, 2:05 AM EDT
Not listed Phase 2 Interventional

Study of Oral Zileuton in the Treatment of Moderate to Severe Facial Acne Vulgaris

NCT00098358
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Zileuton
Drug
Lead sponsor
Critical Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
12
States / cities
San Diego, California • Newnan, Georgia • Louisville, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2007 · Synced Oct 2, 2026, 2:05 AM EDT
Recruiting Phase 2 Interventional

Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07213973
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Povorcitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Farmington, Connecticut + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 2, 2026, 2:05 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne

NCT06316297
View directory record Official record
Conditions
Acne
Interventions
Acne mRNA vaccine, Placebo
Biological · Other
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
79
States / cities
Scottsdale, Arizona • Cerritos, California • Encino, California + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 2, 2026, 2:05 AM EDT
Completed Phase 2 Interventional

BLI1100-202: BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris

NCT01815450
View directory record Official record
Conditions
Acne Vulgaris
Interventions
BLI1100, BLI1100 - modified formulation, Placebo
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
12 Years to 45 Years
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
15
States / cities
Fremont, California • Jacksonville, Florida • Ormond Beach, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2015 · Synced Oct 2, 2026, 2:05 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa

NCT06840392
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
35
States / cities
Birmingham, Alabama • Gilbert, Arizona • Fremont, California + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 2, 2026, 2:05 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Safety and Efficacy of Radio Frequency for the Treatment of Mild to Severe Inflammatory Acne

NCT05830968
View directory record Official record
Conditions
Inflammatory Acne Vulgaris
Interventions
Morpheus8 Applicator Radiofrequency device
Device
Lead sponsor
InMode MD Ltd.
Industry
Eligibility
16 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
4
States / cities
Oro Valley, Arizona • Greenwood Village, Colorado • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 2, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa

NCT05322473
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Sonelokimab (M1095), Adalimumab, Placebo
Drug · Other
Lead sponsor
MoonLake Immunotherapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
15
States / cities
Fountain Valley, California • Los Angeles, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 2, 2026, 2:05 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy Study of Autologous Fibroblasts in the Treatment of Severe Facial Acne Scarring

NCT00642642
View directory record Official record
Conditions
Acne Scarring of the Face
Interventions
Autologous Human Fibroblasts (azficel-T), Placebo
Biological
Lead sponsor
Castle Creek Biosciences, LLC.
Industry
Eligibility
18 Years to 65 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
7
States / cities
Beverly Hills, California • San Diego, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2013 · Synced Oct 2, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa

NCT04019041
View directory record Official record
Conditions
Hidradenitis Suppurativa, Acne Inversa, Suppurative Hidradenitis
Interventions
bermekimab, placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
33
States / cities
Gilbert, Arizona • Huntington Beach, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 2, 2026, 2:05 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT05620836
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Povorcitinib, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
38
States / cities
Scottsdale, Arizona • Arkansas City, Arkansas • Fayetteville, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 2, 2026, 2:05 AM EDT